Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Recommendation of “Buy” from Brokerages

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) has received a consensus recommendation of “Buy” from the six analysts that are covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $17.33.

Several research analysts have commented on TNYA shares. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a research note on Monday, February 3rd. Chardan Capital reaffirmed a “buy” rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a research note on Wednesday, December 18th.

Institutional Trading of Tenaya Therapeutics

Large investors have recently made changes to their positions in the stock. Synovus Financial Corp purchased a new stake in shares of Tenaya Therapeutics during the third quarter valued at $28,000. Woodline Partners LP purchased a new stake in Tenaya Therapeutics in the fourth quarter worth about $28,000. Commerce Bank purchased a new stake in Tenaya Therapeutics in the fourth quarter worth about $29,000. Mariner LLC purchased a new stake in Tenaya Therapeutics in the fourth quarter worth about $30,000. Finally, Ground Swell Capital LLC purchased a new stake in Tenaya Therapeutics in the fourth quarter worth about $32,000. 90.54% of the stock is owned by hedge funds and other institutional investors.

Tenaya Therapeutics Stock Down 6.2 %

NASDAQ TNYA opened at $0.95 on Tuesday. The company has a fifty day moving average of $1.24 and a two-hundred day moving average of $1.95. The firm has a market capitalization of $75.01 million, a price-to-earnings ratio of -0.66 and a beta of 2.84. Tenaya Therapeutics has a 52 week low of $0.68 and a 52 week high of $7.01.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.